Loading patent…
AssigneeGenentech, Inc.
InventorsYinghui GUAN, Yasin SENBABAOGLU, Shannon TURLEY, Yulei WANG
Estimating the term…
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.
A method of identifying an individual having a cancer who may benefit from treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the method comprising determining the expression level of three or more of the following genes in a sample from the individual:
A method for selecting a therapy for an individual having a cancer, the method comprising determining the expression level of three or more of the following genes in a sample from the individual:
A method of treating an individual having a cancer, the method comprising:
A method of treating an individual having a cancer, the method comprising administering to the individual an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, wherein prior to treatment the expression level of three or more of ACTA2, ADAM19, COMP, CTGF, TGFB1, or TGFBR2 in the sample has been determined to be at or above a reference expression level of the three or more genes.
A method of identifying an individual having a cancer who may benefit from treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the method comprising determining the expression level of one or more of the following genes in a sample from the individual:
A method for selecting a therapy for an individual having a cancer, the method comprising determining the expression level of one or more of the following genes in a sample from the individual:
A method of treating an individual having a cancer, the method comprising:
A method of treating an individual having a cancer, the method comprising administering to the individual an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, wherein prior to treatment the expression level of one or more of ACTA2, ADAM19, COMP, CTGF, TGFB1, or TGFBR2 in the sample has been determined to be at or above a reference expression level of the one or more genes, wherein the one or more genes includes at least ADAM19 or COMP.
A method for assessing a response of an individual having a cancer to treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the method comprising:
A method for monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the method comprising:
A method for assessing a response of an individual having a cancer to treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the method comprising:
A method for monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the method comprising:
A method of selecting a therapy for an individual having a cancer, the method comprising:
A kit for identifying an individual having a cancer who may benefit from treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the kit comprising:
A kit for identifying an individual having a cancer who may benefit from treatment with an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist, the kit comprising:
An anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist for use in a method of treating an individual suffering from a cancer, wherein prior to treatment the expression level of three or more of ACTA2, ADAM19, COMP, CTGF, TGFB1, or TGFBR2 has been determined to be at or above a reference expression level of the one or more genes.
An anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist for use in a method of treating an individual suffering from a cancer, wherein prior to treatment the expression level of one or more of ACTA2, ADAM19, COMP, CTGF, TGFB1, or TGFBR2 has been determined to be at or above a reference expression level of the one or more genes, wherein the one or more genes includes at least ADAM19 or COMP.
Use of an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist in the manufacture of a medicament for treating an individual suffering from a cancer, wherein prior to treatment the expression level of three or more of ACTA2, ADAM19, COMP, CTGF, TGFB1, or TGFBR2 has been determined to be at or above a reference expression level of the one or more genes.
Use of an anti-cancer therapy comprising an immunotherapy and a suppressive stromal antagonist in the manufacture of a medicament for treating an individual suffering from a cancer, wherein prior to treatment the expression level of one or more of ACTA2, ADAM19, COMP, CTGF, TGFB1, or TGFBR2 has been determined to be at or above a reference expression level of the one or more genes, wherein the one or more genes includes at least ADAM19 or COMP.
A kit for monitoring a response of an individual having a cancer, the kit comprising:
A kit for monitoring a response of an individual having a cancer, the kit comprising:
Dependencies are inferred from the claim text.